The HIV-1 protein Vpr has glucocorticoid receptor coactivator activity, potently increasing the sensitivity of glucocorticoid target tissues to cortisol. Patients with AIDS and normal cortisol secretion have manifestations compatible with glucocorticoid hypersensitivity of the immune system, such as suppression of innate and cellular immunities. The latter can be explained by glucocorticoid-induced inhibition of cytokine networks regulating innate and Th1-driven cellular immunity. We demonstrated that extracellularly administered Vpr protein dose-dependently potentiated glucocorticoid-induced suppression of both mRNA expression and secretion of IL-12 subunit p35 and IL-12 holo-protein, but not IL-12 subunit p40 or IL-10, by human monocytes/macrophages stimulated with LPS or heat-killed, formalin-fixed Staphylococcus aureus (Cowan strain 1). This effect was inhibited by the glucocorticoid receptor antagonist RU 486. Also, Vpr changed the expression of an additional five glucocorticoid-responsive genes in the same direction as dexamethasone and was active in potentiating the trans-activation, but not the trans-repression, properties of the glucocorticoid receptor on nuclear factor κB- or activating protein 1-regulated simple promoters. Thus, extracellular Vpr enhances the suppressive actions of the ligand-activated glucocorticoid receptor on IL-12 secretion by human monocytes/macrophages. Through this effect, Vpr may contribute to the suppression of innate and cellular immunities of HIV-1-infected individuals and AIDS patients.

Infection with HIV-1 leads to a decline in CD4 T cell numbers and an impaired cellular immune response, permitting development of AIDS, through elimination of these cells by the viral infection (1, 2, 3). In parallel, the deficit in innate and cellular immunities seen in HIV-1-infected patients is also characterized by suppression of the cytolytic activities of NK cells and cytotoxic T lymphocytes and by inhibition of T cell proliferation and of delayed-type hypersensitivity reactions (3). One important mechanism of this immune dysregulation is a selective impairment of monocytes/macrophages, dendritic cells, and Th1 lymphocytes and their cytokine networks (4, 5). Thus, the production of IL-12 and IFN-γ by NK and T cells, two cytokines that regulate and promote innate, cellular, and antiviral immunities, is decreased during HIV-1 infection (6).

Cytokines that are responsible for polarization of Th-type responses are of particular interest in AIDS (7). IL-12 is a central inducer of the Th1 response and cell-mediated immunity by stimulating the production of IFN-γ from NK and T cells and by inducing differentiation and proliferation of Th1-type cells (8). Thus, this cytokine, which is produced by APCs of the innate immune system, such as monocytes/macrophages and dendritic cells, appears to be critical for the promotion of cellular and, hence, antiviral immunities (9, 10, 11). IL-12 is a 75-kDa heterodimeric molecule composed of p35 and p40 subunits encoded by two separate genes (12, 13, 14). Both p35 and p40 are up-regulated in response to various stimuli, including intracellular bacteria or viruses, several endotoxins such as LPS, and intracellular proteins released by necrotic cells (14, 15, 16, 17, 18, 19). IFN-γ, on the other hand, does not stimulate IL-12 production, but functions as a costimulatory signal, priming the cells to produce higher amounts of IL-12 after appropriate stimuli (20).

PBMC or whole blood cultures from HIV-infected individuals express marked deficiency in the production of both IL-12 p40 and p70 compared with cells from healthy individuals (6). This deficiency is observed across a broad panel of stimuli derived from infectious pathogens (21). The impairment of IL-12 production in HIV-1-infected individuals appears to be selective, since no variation in the secretion of TNF-α, IL-1β, or IL-10 has been found (22). The low production of IL-12 may be one of the critical factors for the impaired innate and cellular immunity in HIV-1-infected patients, since exogenous IL-12 is able to partially restore the depressed T cell proliferation, T and NK cell production of IL-2 and IFN-γ, and NK lytic activities in cells from HIV-1-infected individuals (23). The mechanism(s), however, underlying the reduced IL-12 production in HIV-1-infected patients remains poorly understood.

HIV-1 encodes a 96-aa, virion-associated accessory protein, Vpr, which has multiple, diverse functions (2, 24, 25). Vpr enhances the viral replication in monocyte- and lymphocyte-derived cell lines (26, 27, 28) and functions as a transcriptional activator of several viral promoters, including the HIV-1 long terminal repeat promoter (29, 30, 31, 32), and causes cell cycle arrest at the G2/M phase (33, 34, 35). Vpr may also contribute to nuclear translocation of the HIV-1 preintegration complex, possibly helping HIV-1 to efficiently infect nondividing cells, such as monocytes/macrophages and resting lymphocytes (36, 37, 38). Because Vpr is virion associated, it is delivered to the infected cells with the viral particle at an early phase of HIV-1 infection, affecting local infected lymphocytes, monocytes/macrophages, and dendritic cells (39). However, the same viral polypeptide is also expressed and secreted by infected cells of the host after successful integration of the HIV-1 provirus into the host genome (40). Indeed, this protein is detected in the extracellular fluids of HIV-1-infected patients, such as plasma and cerebrospinal fluid. Since extracellularly administered synthetic Vpr is bioactive, causing cell cycle arrest by penetrating the cell membrane, Vpr secreted into the extracellular space may exert its effects on proximal and distal cells and tissues, which are not infected by the virus (41).

We previously reported that Vpr dramatically enhances glucocorticoid receptor (GR)2 activity in several different cell lines, functioning as a potent coactivator of the GR, through a classic LXXLL coactivator signature motif (30). We further demonstrated that Vpr behaved as an adaptor molecule between promoter-bound transcription factors and p300/CBP coactivators in a glucocorticoid-responsive promoter (42). We also reported that nuclear receptor-responsive promoters employed the same set of coactivators and transcription-elongation complexes as the HIV-1 long terminal repeat, and that Vpr potentiated both types of promoter activities through the same mechanism, cooperating with host coactivators (43).

Glucocorticoids strongly inhibit IL-12 production from peripheral monocytes/macrophages, and this was suggested to be a major mechanism responsible for their selective suppression of Th1 functions and cellular immunity (44, 45, 46). Since Vpr functions as an enhancer of glucocorticoid activity, we hypothesized that this viral protein might contribute to the impaired IL-12 production seen in AIDS patients. We found that extracellularly administered Vpr suppressed both mRNA and protein production of IL-12, but not IL-10, from human peripheral monocytes. This viral peptide potentiated the effect of dexamethasone on IL-12 production, and this effect was inhibited by the glucocorticoid antagonist RU 486. The actions of Vpr and dexamethasone on the expression of other glucocorticoid-regulated mRNAs were similar. These results indicate that Vpr may inhibit IL-12 production by enhancing endogenous glucocorticoid action, potentially contributing to the innate and cellular immunity deficits of HIV-1-positive individuals and AIDS patients.

Recombinant Vpr protein was produced using a baculovirus expression system. Vpr cDNA was amplified by PCR using primers 5′-ATGATAGGATCCATGGAACAAGCCCCAGAAGACC-3′ and 5′-ACATGTAAGCTTCTAGGATCTACTGGCTC-3′ from the pCDNA3-Vpr that contains the wild-type Vpr sequence of the HIV-1 NLA1 strain (30). The pFastBacHTb-Vpr was constructed by subcloning Vpr cDNA into BamHI and HindIII sites of pFastBacHTb (Life Technologies, Gaithersburg, MD) and expressed six-histidine-tagged Vpr protein in insect cells. Viruses that contain the His-Vpr sequence were isolated from DH10bac cells (Life Technologies) transformed by pFastBacHTb-Vpr. Sf9 cells were then infected with such viruses, and the cell lysates and culture media were collected to test for the expression of Vpr. A significant quantity of His-Vpr was found in the cell lysates, and subsequent purification was conducted using the cell pellets.

The method for the purification of recombinant His-Vpr is as follows. Frozen cell pellets were resuspended in lysis buffer (20 mM potassium phosphate (pH 7.4), 0.5 M NaCl, 5 mM imidazole, 1% Tween 20, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 mM PMSF) and sonicated to disrupt the cell membranes. The homogenates were centrifuged at 14,000 rpm for 15 min, and the supernatants were collected and loaded on a His-tag affinity column (Amersham Pharmacia Biotech, Piscataway, NJ). His-Vpr was eluted using elution buffer (20 mM potassium phosphate (pH 7.4), 0.5 M NaCl, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM PMSF, and 200 mM or 400 mM imidazole) and was further concentrated using Centriprep YM-10 (nominal m.w. limit, 10,000) and YM-30 (nominal m.w. limit, 30,000; Millipore, Bedford, MA). The fraction filtered with YM-10 was used to dissolve the HIV-1 reverse transcriptase (Pol; AIDS Research and Reagent Program, National Institutes of Health, Bethesda, MD), which was used as a control for purified His-Vpr. In all procedures described above we used no steroids including glucocorticoids. A SilverXpress silver staining kit (Invitrogen, Carlsbad, CA) was used to visualize proteins run on the SDS-PAGE gel following the manufacturer’s instructions, and gels were dried on paper filters. His-Vpr, separated on an SDS-PAGE gel, was transferred to the nitrocellulose membrane and blotted with anti-Vpr Ab (a gift from Dr. J. B. Kopp, National Institutes of Health) or anti-His Ab (Santa Cruz Biotechnology, Santa Cruz, CA).

IL-12 p70, IL-12 p40, and IL-10 were measured by specific ELISA kits purchased from R&D Systems (Minneapolis, MN). The absorbance of each sample was measured with the microplate reader (model 550; Bio-Rad, Richmond, CA), and results were transformed to cytokine concentration (in picograms per milliliter) using a standard curve computed by Microplate Manager III Macintosh data analysis software (Bio-Rad).

Human monocytes were obtained from HIV-1-negative healthy donors. Mononuclear cells were isolated in lymphocyte separation medium, and the monocytes were purified by the counterflow centrifugal elutriation as reported previously (47). The monocytes were cultured at 5 × 105 cells/ml in RPMI 1640 medium supplemented with 10% FBS, 1% glutamine, and 50 μg/ml gentamicin to yield a final volume of 1 ml in 24-well plates. In a separate experiment dextran/charcoal-treated FBS was used instead of regular FBS. Cells were primed with 100 ng/ml of IFN-γ (R&D Systems) and cultured in the presence of increasing concentrations of Vpr in the absence or the presence of several concentrations of dexamethasone and/or RU 486, followed by stimulation with 1 μg/ml of LPS or 0.1% heat-killed, formalin-fixed Staphylococcus aureus (Cowan strain 1; SAC) in 5% CO2 at 37°C for 18 h. After incubation, the plates were centrifuged, and cell-free medium was collected and stored at −70°C for determination of p70 and p40 components of IL-12 and IL-10. To minimize variation of results from different donors, the experiments were repeated at least four times using peripheral monocytes from different individuals. The mean ± SE of LPS-induced levels of p70, p40, and IL-10 were 403 ± 16.9, 8956 ± 255, and 125.2 ± 5 pg/ml, respectively.

Human monocytes were cultured at 1.5 × 107 cells in the presence of 10 ng/ml of Vpr and/or 10−8 M dexamethasone, followed by stimulation with 1 μg/ml of LPS. Total RNA was isolated by using TRIzol (Life Technologies, Gaithersburg, MD) according to the manufacturer’s instruction. The cDNAs were reverse transcribed with TaqMan reverse transcription reagents (PE Applied Biosystems, Foster City, CA). mRNA levels of p35 and p40, and IL-10 were determined using TaqMan cytokine gene expression plate I (PE Applied Biosystems) on the ABI PRISM 7700 sequence detection system, as previously reported. mRNA levels of human CD44, human Toll-like receptor 4, and indolamine 2,3-dioxygenase; the human macrophage receptor with collagenase structure and thrombospondin 1, which are negatively or positively regulated by glucocorticoids, respectively, were determined using primer sets as described previously (48).

Human cervical carcinoma HeLa cells were kept in DMEM containing 10% FBS, 50 μg/ml of streptomycin, and 50 U/ml of penicillin. They were transfected with 1.0 μg/well of pCDNA3-Vpr together with 1.5 μg/well of (IκB)3-luciferase (Luc) or AP-1-tk81-Luc and 0.5 μg/well of pSV40-β-Gal by the lipofectin (Life Technologies) method as previously described (30). pRSV-RelA (0.5 μg/well) or tetradecanoyl phorbol acetate (10−9 M) was cotransfected or added to examine NF-κB or AP-1 activities, respectively. To keep the same amount of DNA, Bluescript SK+ and/or pCDNA3 were added. After transfection, the media were replaced with regular medium, and cells were cultured for an additional 24 h. Then, cells were stimulated with 1 × 10−6 M dexamethasone or vehicle, and cell lysates were collected for the luciferase and β-galactosidase assays after an additional 24 h. These enzyme activities were determined as previously described (49). pRSV-RelA, which expresses the p65 component of NF-κB, was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. pCDNA3-Vpr, which expresses wild-type Vpr, was described previously. (IκB)3-Luc, which contains three κB-responsive elements from the IκB promoter, was a gift from Dr. T. Fujita (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). AP-1-tk81-Luc, which has four AP-1-responsive elements upstream of a proximal portion of the herpes simplex thymidine kinase promoter, was a gift from Dr. C. Bamberger (IHF, Institute for Hormone and Fertility Research, Hamburg, Germany). Mouse mammary tumor virus (MMTV) promoter-luciferase (pMMTV-Luc), which has the full-length MMTV promoter that contains four glucocorticoid-responsive elements (GREs), was provided by Dr. G. L. Hager (National Cancer Institute, Bethesda, MD). Bluescript SK+, pCDNA3, and pSV40-β-galactosidase were purchased from Stratagene (La Jolla, CA), Invitrogen (Carlsbad, CA), and Promega (Madison, WI), respectively.

All data are presented as the mean ± SE. Statistical analyses were performed by one-way ANOVA, followed by Student’s t test after appropriate Bonferroni correction.

Purified, insect cell-derived Vpr protein showed a single band with a Mr of 17 kDa detected with the silver-staining method on an SDS-PAGE gel (Fig. 1,A). The protein band with the same Mr was detected with anti-Vpr (i) or anti-His (ii) Ab in a Western blot (Fig. 1,B). The addition of increasing concentrations of His-Vpr resulted in a dose-dependent inhibition of IL-12 p70 production from LPS-stimulated human monocytes (Fig. 2,A). Very low concentrations of Vpr, such as 0.1 ng/ml, already suppressed IL-12 production to 84% of baseline. The Vpr effect became more significant at concentrations of 1 and 10 ng/ml with a cytokine production of 73, and 65% of baseline, respectively. The same concentration of the control protein, HIV-1 Pol, dissolved in the void fluid from YM-10 concentration during Vpr purification, did not affect p70 production. To determine whether the effects of Vpr on IL-12 production were limited to LPS-stimulated IL-12, monocytes were treated with SAC instead of LPS and showed the same effect (Fig. 2 B).

FIGURE 1.

Purified Vpr protein produced by baculovirus-infected insect cells. A, His-Vpr was detected as a single band in an SDS-PAGE gel. One microgram of purified His-Vpr was loaded and run on a 10–20% SDS-PAGE gel. The protein band was then visualized with the SilverXpress silver staining kit, and the gel was dried. B, Vpr protein was detected by anti-Vpr and anti-His Abs in a Western blot analysis. An aliquot of 100 ng of purified Vpr and the control protein, Pol, were loaded and separated on a 10–20% SDS-PAGE gel. Proteins were blotted on a nitrocellulose membrane and detected with anti-Vpr (i) or anti-His (ii) Abs.

FIGURE 1.

Purified Vpr protein produced by baculovirus-infected insect cells. A, His-Vpr was detected as a single band in an SDS-PAGE gel. One microgram of purified His-Vpr was loaded and run on a 10–20% SDS-PAGE gel. The protein band was then visualized with the SilverXpress silver staining kit, and the gel was dried. B, Vpr protein was detected by anti-Vpr and anti-His Abs in a Western blot analysis. An aliquot of 100 ng of purified Vpr and the control protein, Pol, were loaded and separated on a 10–20% SDS-PAGE gel. Proteins were blotted on a nitrocellulose membrane and detected with anti-Vpr (i) or anti-His (ii) Abs.

Close modal
FIGURE 2.

A, Vpr suppressed the secretion of IL-12 p70 by LPS-stimulated human peripheral monocytes. Human peripheral monocytes were incubated with increasing concentrations of Vpr or 10 ng/ml of Pol. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation alone. ∗, p < 0.05; ∗∗, p < 0.01 (compared with baseline). B, Vpr suppressed the secretion of IL-12 p70 from the human peripheral monocytes stimulated with SAC in addition to LPS. Human peripheral monocytes were incubated with 10 ng/ml of Vpr with LPS or SAC. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline). C and D, Vpr did not change the secretion of IL-12 p40 (C) and IL-10 (D) by LPS-stimulated human peripheral monocytes. Human peripheral monocytes were incubated with increasing concentrations of Vpr or 10 ng/ml of Pol. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation.

FIGURE 2.

A, Vpr suppressed the secretion of IL-12 p70 by LPS-stimulated human peripheral monocytes. Human peripheral monocytes were incubated with increasing concentrations of Vpr or 10 ng/ml of Pol. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation alone. ∗, p < 0.05; ∗∗, p < 0.01 (compared with baseline). B, Vpr suppressed the secretion of IL-12 p70 from the human peripheral monocytes stimulated with SAC in addition to LPS. Human peripheral monocytes were incubated with 10 ng/ml of Vpr with LPS or SAC. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline). C and D, Vpr did not change the secretion of IL-12 p40 (C) and IL-10 (D) by LPS-stimulated human peripheral monocytes. Human peripheral monocytes were incubated with increasing concentrations of Vpr or 10 ng/ml of Pol. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation.

Close modal

We also tested the effect of Vpr on the production of IL-12 p40 and IL-10 in the same assay system. Neither Vpr nor HIV-1 Pol affected the production of these molecules in LPS-stimulated monocytes (Fig. 2, C and D). Since we reported that Vpr enhances the glucocorticoid effect, functioning as a coactivator of the GR (30), we examined the effects of dexamethasone on the production of IL-12 p70 and p40, and IL-10 to compare with Vpr activity (Fig. 3, A–C). Dexamethasone at 10−8 M suppressed IL-12 p70 and p40, but not IL-10 production in LPS-treated monocytes, as we reported previously. It was equivalent to 10 ng/ml of Vpr for the suppression of production of these cytokines. RU 486, a competitive antagonist for the GR, at a concentration of 10−6 M did not affect the production of any of the cytokines examined by itself, while it completely abolished the suppressive effect of dexamethasone on p70.

FIGURE 3.

Vpr changed IL-12 p70 production by potentiating glucocorticoid action. A–C, Dexamethasone at 10−8 M suppressed the production of IL-12 p70 (A) and IL-12 p40 (B), but not that of IL-10 (C), by LPS-stimulated human peripheral monocytes, and RU 486 abolished its effects. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline). D, RU 486 abolished Vpr-induced suppression of the IL-12 p70 production by LPS-stimulated human peripheral monocytes. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. E, Vpr failed to suppress IL-12 p70 production in the medium with dextran/charcoal-treated FBS. LPS-stimulated human peripheral monocytes were cultured in medium containing regular FBS or dextran-charcoal-treated FBS and incubated with 10 ng/ml of Vpr. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. F, Vpr shifted the dexamethasone titration curve of IL-12 p70 production to the left and downward in LPS-stimulated human peripheral monocytes. LPS-stimulated human peripheral monocytes were incubated with increasing concentrations of dexamethasone in the presence (▪) or the absence (○) of 1 ng/ml of Vpr. Each point represents the mean ± SE percentage of each result compared with the values obtained with LPS stimulation.∗, p < 0.05; ∗∗, p < 0.01 (compared with the values obtained with 10−12 M dexamethasone).

FIGURE 3.

Vpr changed IL-12 p70 production by potentiating glucocorticoid action. A–C, Dexamethasone at 10−8 M suppressed the production of IL-12 p70 (A) and IL-12 p40 (B), but not that of IL-10 (C), by LPS-stimulated human peripheral monocytes, and RU 486 abolished its effects. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline). D, RU 486 abolished Vpr-induced suppression of the IL-12 p70 production by LPS-stimulated human peripheral monocytes. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. E, Vpr failed to suppress IL-12 p70 production in the medium with dextran/charcoal-treated FBS. LPS-stimulated human peripheral monocytes were cultured in medium containing regular FBS or dextran-charcoal-treated FBS and incubated with 10 ng/ml of Vpr. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. F, Vpr shifted the dexamethasone titration curve of IL-12 p70 production to the left and downward in LPS-stimulated human peripheral monocytes. LPS-stimulated human peripheral monocytes were incubated with increasing concentrations of dexamethasone in the presence (▪) or the absence (○) of 1 ng/ml of Vpr. Each point represents the mean ± SE percentage of each result compared with the values obtained with LPS stimulation.∗, p < 0.05; ∗∗, p < 0.01 (compared with the values obtained with 10−12 M dexamethasone).

Close modal

To further investigate the hypothesis that Vpr acts by modulating GR activity, we tested RU 486 on the action of Vpr in the same experiment procedure. RU 486 at 10−6 M completely abolished the suppression of Vpr-induced p70 production, indicating that Vpr enhanced the pathway(s) regulated by the GR (Fig. 3,D). Since it is likely that Vpr potentiated the glucocorticoid effect present in regular FBS, we tested the effects of Vpr on IL-12 p70 production in medium supplemented with dextran/charcoal-treated FBS. As expected, Vpr did not suppress p70, while it was fully active in the medium containing FBS (Fig. 3 E).

We also tested the effects of Vpr in the presence of increasing concentrations of dexamethasone. Incubation of these cells with 1 ng/ml of Vpr shifted the dexamethasone dose-response curve of p70 production to the left and downward, suggesting that it potentiated the effect of administered dexamethasone on p70 production. The Vpr effect was particularly significant at concentrations from 10−10–10−9 M dexamethasone, which are equivalent to physiologic concentrations of cortisol in humans (Fig. 3 F).

We next examined the effects of Vpr on the mRNA expression of IL-12 p40 and p35, and IL-10 in human peripheral monocytes using TaqMan cytokine gene plate I. Expression of IL-12 p35 mRNA was suppressed by Vpr, while that of IL-12 p40 and IL-10 was not changed. In a parallel experiment, 10−8 M dexamethasone suppressed both IL-12 p35 and p40 mRNA expression, but did not change the abundance of IL-10 mRNA. Vpr and 10−8 M dexamethasone cooperatively suppressed IL-12 p35 mRNA levels (Fig. 4). We also measured the mRNA concentrations of CD44, Toll-like receptor 4, and indolamine 2,3-dioxygenase, all of which are strongly suppressed by glucocorticoids, and macrophage receptor with collagenous structure and thrombospondin 1, which are potently stimulated by these hormones. A concentration of 10 ng/ml of Vpr or 10−8 M dexamethasone changed the expression of all tested mRNAs in the same direction, suggesting that Vpr also affects the gene expression of other glucocorticoid-regulated genes (Fig. 5).

FIGURE 4.

Vpr suppressed the production of IL-12 p35 mRNA, but not IL-12 p40 and IL-10, in LPS-stimulated human peripheral monocytes. Peripheral human monocytes were incubated with vehicle (−), 10−8 M dexamethasone (Dex), or 10 ng/ml Vpr and stimulated with LPS. Total RNA was collected, and the mRNA abundance of indicated polypeptides was determined using the TaqMan PCR procedure. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline).

FIGURE 4.

Vpr suppressed the production of IL-12 p35 mRNA, but not IL-12 p40 and IL-10, in LPS-stimulated human peripheral monocytes. Peripheral human monocytes were incubated with vehicle (−), 10−8 M dexamethasone (Dex), or 10 ng/ml Vpr and stimulated with LPS. Total RNA was collected, and the mRNA abundance of indicated polypeptides was determined using the TaqMan PCR procedure. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline).

Close modal
FIGURE 5.

Vpr and dexamethasone induced the same direction changes in the expression of glucocorticoid-regulated genes. LPS-stimulated human peripheral monocytes were incubated with vehicle (−), 10 ng/ml of Vpr, or 10−8 M dexamethasone (Dex). Total RNA was collected, and the mRNA abundance of the indicated polypeptides was determined using the TaqMan PCR procedure. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline).

FIGURE 5.

Vpr and dexamethasone induced the same direction changes in the expression of glucocorticoid-regulated genes. LPS-stimulated human peripheral monocytes were incubated with vehicle (−), 10 ng/ml of Vpr, or 10−8 M dexamethasone (Dex). Total RNA was collected, and the mRNA abundance of the indicated polypeptides was determined using the TaqMan PCR procedure. Bars represent the mean ± SE percentage of each result compared with the values obtained with LPS stimulation. ∗∗, p < 0.01 (compared with baseline).

Close modal

Vpr suppressed IL-12 p35 mRNA production, but not that of IL-12 p40, and it was active on both positively and negatively regulated genes by dexamethasone. Since GR has two major activities, GRE-mediated trans-activation of the glucocorticoid-responsive promoters and trans-repression of promoters regulated by other transcription factors through the protein-protein interactions (50), the above discrepancy might result from selective action of Vpr on these GR activities. We previously showed that Vpr enhanced trans-activation by the GR through its coactivator activity (30). Here we tested Vpr on GR-induced trans-repression of NF-κB- and AP-1-responsive promoters in transient transfection-based reporter assay systems. The IL-12 p40 promoter contains functional NF-κB- and AP-1-responsive elements, and glucocorticoid interference with the transcriptional activity of these factors may explain their suppressive effect of dexamethasone on p40 mRNA expression (51, 52). Interestingly, Vpr did not affect dexamethasone-suppressed NF-κB- or AP-1-responsive promoter activities, while it enhanced GR activity on the MMTV promoter, as previously reported (30) (Fig. 6). These results indicate that Vpr is effective primarily in GRE-mediated trans-activation activity, but it appears to have no effect on its trans-repressive actions on other transcription factors, such as NF-κB and AP-1.

FIGURE 6.

Vpr did not change the trans-repression activity of GR on the NF-κB- and AP-1-responsive promoters. The Vpr effect was examined on the MMTV- (A), NF-κB- (B), and AP-1- (C) responsive promoters in HeLa cells. Bars show the mean ± SE luciferase activity normalized for β-galactosidase activity in the absence or the presence of 10−6 M dexamethasone. ∗∗, p < 0.01; n.s., p > 0.05 (compared with baseline).

FIGURE 6.

Vpr did not change the trans-repression activity of GR on the NF-κB- and AP-1-responsive promoters. The Vpr effect was examined on the MMTV- (A), NF-κB- (B), and AP-1- (C) responsive promoters in HeLa cells. Bars show the mean ± SE luciferase activity normalized for β-galactosidase activity in the absence or the presence of 10−6 M dexamethasone. ∗∗, p < 0.01; n.s., p > 0.05 (compared with baseline).

Close modal

We demonstrated that extracellularly administered Vpr moderately suppressed IL-12 production, measured as the p70 dimeric molecule from IFN-γ-primed, LPS-stimulated human peripheral monocytes, suggesting downstream suppression of innate and Th1-type cellular immunity by this viral protein. Vpr, on the other hand, did not change the production of IL-10, which plays a critical role in maintaining Th2-type humoral immunity. Vpr’s effect on IL-12 and IL-10 production and mRNA expression was similar, but not identical, with to of dexamethasone (44, 46). The GR antagonist, RU 486, or the use of dextran/charcoal-treated FBS, which strips steroid hormones from serum, completely abolished Vpr’s effect on IL-12 secretion, and 1 ng/ml of Vpr shifted the dose-response curve of dexamethasone on IL-12 production to the left and downward, suggesting that this viral protein made human peripheral monocyte/macrophage secretion of IL-12 more sensitive to the suppressive actions of glucocorticoids. Furthermore, Vpr and dexamethasone induced concordant mRNA changes in five different glucocorticoid-responsive genes. These results strongly support the hypothesis that extracellular Vpr enters human cells and suppresses IL-12 production by enhancing ligand-bound GR activity.

Vpr enhanced the activity of glucocorticoids by suppressing IL-12 p35, but not p40, expression. Since the IL-12 p35 subunit is produced in far smaller amounts than the p40 subunit, HIV-1 may efficiently suppress IL-12 p70 production by down-regulating this rate-limiting component of IL-12 (18). While Vpr did not change mRNA or protein levels of IL-12 p40, however, dexamethasone did. The promoter of the IL-12 p40 subunit gene contains functional cis-acting sequences, including responsive elements for NF-κB and AP-1, which are key transcription factors in inflammation (20, 51, 52, 53). Since glucocorticoids induce strong inhibition of NF-κB and AP-1 through protein-protein interactions between ligand-activated GR and each of these transcription factors, it is likely that glucocorticoids suppress p40 production by inhibiting the activity of these factors (54).

The mechanism of p35 promoter suppression by glucocorticoids is not well understood. In humans there are two types of p35 transcripts, which are regulated by an upstream promoter characterized by a CpG island and a downstream promoter containing a TATA box (55). The former is active in B cell lines transformed with EBV, while the latter plays a major role in monocytes/macrophages. The latter promoter contains IFN-responsive elements that strongly influence p35 expression (56). The same promoter also contains several half-GREs and responsive elements for NF-κB, AP-1, Sp 1, and C/EBP; however, the functional significance of these sequences has not been determined as yet (56). Because our results indicate that Vpr does not affect the suppressive effect of GR on simple NF-κB- or AP-1-responsive promoters (Fig. 6), we concluded that Vpr might not generically disrupt the proper function of the transcriptosome formed by these transcription factors; however, the functional significance of half-GREs and whether they are influenced by Vpr are not known. Our data suggest that Vpr might enhance the trans-activational effect of glucocorticoids on the transcription of a gene(s) coding for a protein(s) that reduces p35 promoter activity and hence indirectly suppress p35 expression and IL-12 production.

Vpr is incorporated into the virion, and its activity may be important in the early stages of the viral life cycle (39). Although we have not tested the activities of virion-associated Vpr, this protein, released from the virion or produced de novo by the infecting virus, may inhibit the secretion of IL-12 from monocytes/macrophages or dendritic cells at local sites of infection. Thus, Vpr may contribute to the inefficient activation of NK cells, blockade of Ag recognition, and deficient production of sensitized cytotoxic T lymphocytes with anti-viral specificity that characterize HIV-1-infected AIDS patients. Through these effects it could play an important role in the successful infection and proliferation of the HIV-1 virus. We also demonstrated that extracellular Vpr changed the expression of an additional five glucocorticoid-regulated genes in the same direction as dexamethasone. This result indicates that Vpr may regulate numerous glucocorticoid-responsive genes, regardless of actual infection of cells, through enhancing the trans-activation activity of the GR even at normal or low concentrations of circulating glucocorticoids. Indeed, AIDS patients have several manifestations seen in typical glucocorticoid excess states, such as myopathy, muscle wasting, dyslipidemia, and visceral obesity-related insulin resistance, in addition to immunosuppression similar to that induced by pharmacologic levels of glucocorticoids (57, 58, 59, 60, 61, 62, 63, 64). It is possible that extracellular Vpr may contribute to the development of these pathologic states; thus, inhibition of Vpr coactivator activity by neutralizing Ab to Vpr or administration of RU 486 might help improve the clinical manifestations and disease course of AIDS patients.

We thank Dr. G. N. Pavlakis for helpful discussion, Dr. J. B. Kopp for providing anti-Vpr Ab, and Drs. T. Fujita, C. Bamberger, and G. L. Hager for providing their plasmids. We also thank Dr. J. Sidiqqi and K. Zachman for superb technical assistance.

2

Abbreviations used in this paper: GR, glucocorticoid receptor; GRE, glucocorticoid-responsive element; MMTV, mouse mammary tumor virus; SAC, Staphylococcus aureus (Cowan strain 1).

1
Fahey, J. L., J. M. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, J. V. Giorgi.
1990
. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
N. Engl. J. Med.
322
:
166
2
Pavlakis, G. N..
1996
. The molecular biology of HIV-1. V. T. DeVita, and S. Hellman, and S. A. Rosenberg, eds.
AIDS: Diagnosis, Treatment and Prevention
45
Lippincott Raven, Philadelphia.
3
Gandhi, R. T., B. D. Walker.
2002
. Immunologic control of HIV-1.
Annu. Rev. Med.
53
:
149
4
Clerici, M., M. L. Fusi, S. Ruzzante, S. Piconi, M. Biasin, D. Arienti, D. Trabattoni, M. L. Villa.
1997
. Type 1 and type 2 cytokines in HIV infection-a possible role in apoptosis and disease progression.
Ann. Med.
29
:
185
5
Copeland, K. F., J. L. Heeney.
1996
. T helper cell activation and human retroviral pathogenesis.
Microbiol. Rev.
60
:
722
6
Ma, X., L. J. Montaner.
2000
. Proinflammatory response and IL-12 expression in HIV-1 infection.
J. Leukocyte Biol.
68
:
383
7
Romagnani, S., G. Del Prete, R. Manetti, A. Ravina, F. Annunziato, M. De Carli, M. Mazzetti, M. P. Piccinni, M. M. D’Elios, P. Parronchi, et al
1994
. Role of TH1/TH2 cytokines in HIV infection.
Immunol. Rev.
140
:
73
8
Trinchieri, G..
1998
. Proinflammatory and immunoregulatory functions of interleukin-12.
Int. Rev. Immunol.
16
:
365
9
D’Andrea, A., M. Rengaraju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Kobayashi, D. Young, E. Nickbarg, et al
1992
. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
J. Exp. Med.
176
:
1387
10
Heufler, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G. Trinchieri, A. Enk, R. M. Steinman, N. Romani, G. Schuler.
1996
. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells.
Eur. J. Immunol.
26
:
659
11
Chehimi, J., C. Paganin, I. Frank, S. Chouaib, S. Starr, G. Trinchieri.
1995
. Interleukin-12 in the pathogenesis and therapy of HIV disease.
Res. Immunol.
146
:
605
12
Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, G. Trinchieri.
1989
. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.
J. Exp. Med.
170
:
827
13
Gubler, U., A. O. Chua, D. S. Schoenhaut, C. M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A. G. Wolitzky, P. M. Quinn, P. C. Familletti, et al
1991
. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor.
Proc. Natl. Acad. Sci. USA
88
:
4143
14
Ma, X., H. Riemann, G. Gri, G. Trinchieri.
1998
. Positive and negative regulation of interleukin-12 gene expression.
Eur. Cytokine Network
9
:
54
15
Babik, J. M., E. Adams, Y. Tone, P. J. Fairchild, M. Tone, H. Waldmann.
1999
. Expression of murine IL-12 is regulated by translational control of the p35 subunit.
J. Immunol.
162
:
4069
16
Bette, M., S. C. Jin, T. Germann, M. K. Schafer, E. Weihe, E. Rude, B. Fleischer.
1994
. Differential expression of mRNA encoding interleukin-12 p35 and p40 subunits in situ.
Eur. J. Immunol.
24
:
2435
17
Heinzel, F. P., R. M. Rerko, P. Ling, J. Hakimi, D. S. Schoenhaut.
1994
. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon.
Infect. Immun.
62
:
4244
18
Snijders, A., C. M. Hilkens, T. C. van der Pouw Kraan, M. Engel, L. A. Aarden, M. L. Kapsenberg.
1996
. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit.
J. Immunol.
156
:
1207
19
Hayes, M. P., J. Wang, M. A. Norcross.
1995
. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-γ of lipopolysaccharide-inducible p35 and p40 genes.
Blood
86
:
646
20
Murphy, K. M., W. Ouyang, J. D. Farrar, J. Yang, S. Ranganath, H. Asnagli, M. Afkarian, T. L. Murphy.
2000
. Signaling and transcription in T helper development.
Annu. Rev. Immunol.
18
:
451
21
Marshall, J. D., J. Chehimi, G. Gri, J. R. Kostman, L. J. Montaner, G. Trinchieri.
1999
. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals.
Blood
94
:
1003
22
Chehimi, J., S. E. Starr, I. Frank, A. D’Andrea, X. Ma, R. R. MacGregor, J. Sennelier, G. Trinchieri.
1994
. Impaired interleukin 12 production in human immunodeficiency virus-infected patients.
J. Exp. Med.
179
:
1361
23
Clerici, M., D. R. Lucey, J. A. Berzofsky, L. A. Pinto, T. A. Wynn, S. P. Blatt, M. J. Dolan, C. W. Hendrix, S. F. Wolf, G. M. Shearer.
1993
. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro.
Science
262
:
1721
24
Emerman, M..
1996
. HIV-1, Vpr and the cell cycle.
Curr. Biol.
6
:
1096
25
Cohen, E. A., R. A. Subbramanian, H. G. Gottlinger.
1996
. Role of auxiliary proteins in retroviral morphogenesis.
Curr. Top. Microbiol. Immunol.
214
:
219
26
Goh, W. C., M. E. Rogel, C. M. Kinsey, S. F. Michael, P. N. Fultz, M. A. Nowak, B. H. Hahn, M. Emerman.
1998
. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.
Nat. Med.
4
:
65
27
Ayyavoo, V., A. Mahboubi, S. Mahalingam, R. Ramalingam, S. Kudchodkar, W. V. Williams, D. R. Green, D. B. Weiner.
1997
. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor κB.
Nat. Med.
3
:
1117
28
Subbramanian, R. A., A. Kessous-Elbaz, R. Lodge, J. Forget, X. J. Yao, D. Bergeron, E. A. Cohen.
1998
. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages.
J. Exp. Med.
187
:
1103
29
Cohen, E. A., E. F. Terwilliger, Y. Jalinoos, J. Proulx, J. G. Sodroski, W. A. Haseltine.
1990
. Identification of HIV-1 vpr product and function.
J. Acquired Immune Defic. Syndr.
3
:
11
30
Kino, T., A. Gragerov, J. B. Kopp, R. H. Stauber, G. N. Pavlakis, G. P. Chrousos.
1999
. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor.
J. Exp. Med.
189
:
51
31
Sawaya, B. E., K. Khalili, J. Gordon, R. Taube, S. Amini.
2000
. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome.
J. Biol. Chem.
275
:
35209
32
Sherman, M. P., C. M. de Noronha, D. Pearce, W. C. Greene.
2000
. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G2 cell cycle arrest.
J. Virol.
74
:
8159
33
Re, F., D. Braaten, E. K. Franke, J. Luban.
1995
. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
J. Virol.
69
:
6859
34
He, J., S. Choe, R. Walker, P. Di Marzio, D. O. Morgan, N. R. Landau.
1995
. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
J. Virol.
69
:
6705
35
Di Marzio, P., S. Choe, M. Ebright, R. Knoblauch, N. R. Landau.
1995
. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.
J. Virol.
69
:
7909
36
Popov, S., M. Rexach, G. Zybarth, N. Reiling, M. A. Lee, L. Ratner, C. M. Lane, M. S. Moore, G. Blobel, M. Bukrinsky.
1998
. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex.
EMBO J.
17
:
909
37
Heinzinger, N. K., M. I. Bukinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M. A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, M. Emerman.
1994
. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91
:
7311
38
Vodicka, M. A., D. M. Koepp, P. A. Silver, M. Emerman.
1998
. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.
Genes Dev.
12
:
175
39
Paxton, W., R. I. Connor, N. R. Landau.
1993
. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
J. Virol.
67
:
7229
40
Levy, D. N., Y. Refaeli, R. R. MacGregor, D. B. Weiner.
1994
. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
91
:
10873
41
Henklein, P., K. Bruns, M. P. Sherman, U. Tessmer, K. Licha, J. Kopp, C. M. de Noronha, W. C. Greene, V. Wray, U. Schubert.
2000
. Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest.
J. Biol. Chem.
275
:
32016
42
Kino, T., A. Gragerov, O. Slobodskaya, M. Tsopanomichalou-Nglotsou, G. P. Chrousos, G. N. Pavlakis.
2002
. Human immunodeficiency virus type-1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.
J. Virol.
76
:
9724
43
Kino, T., O. Slobodskaya, G. N. Pavlakis, G. P. Chrousos.
2002
. Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex.
J. Biol. Chem.
277
:
2396
44
Elenkov, I. J., G. P. Chrousos.
1999
. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease.
Trends Endocrinol. Metab.
10
:
359
45
Elenkov, I. J., E. L. Webster, D. J. Torpy, G. P. Chrousos.
1999
. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects.
Ann. NY Acad. Sci.
876
:
1
46
Elenkov, I. J., R. L. Wilder, G. P. Chrousos, E. S. Vizi.
2000
. The sympathetic nerve, an integrative interface between two supersystems: the brain and the immune system.
Pharmacol. Rev.
52
:
595
47
Link, A. A., T. Kino, J. A. Worth, J. L. McGuire, M. L. Crane, G. P. Chrousos, R. L. Wilder, I. J. Elenkov.
2000
. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes.
J. Immunol.
164
:
436
48
Galon, J., D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein, J. J. O’Shea, G. P. Chrousos, S. R. Bornstein.
2002
. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells.
FASEB J.
16
:
61
49
Kino, T., J. B. Kopp, G. P. Chrousos.
2000
. Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology.
J. Steroid Biochem. Mol. Biol.
75
:
283
50
Bamberger, C. M., H. M. Schulte, G. P. Chrousos.
1996
. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids.
Endocr. Rev.
17
:
245
51
Zhu, C., K. Gagnidze, J. H. Gemberling, S. E. Plevy.
2001
. Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter: demonstration of novel functional elements by a reductionist approach.
J. Biol. Chem.
276
:
18519
52
Murphy, T. L., M. G. Cleveland, P. Kulesza, J. Magram, K. M. Murphy.
1995
. Regulation of interleukin 12 p40 expression through an NF-κB half-site.
Mol. Cell Biol.
15
:
5258
53
Plevy, S. E., J. H. Gemberling, S. Hsu, A. J. Dorner, S. T. Smale.
1997
. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins.
Mol. Cell Biol.
17
:
4572
54
McKay, L. I., J. A. Cidlowski.
1999
. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways.
Endocr. Rev.
20
:
435
55
Hayes, M. P., F. J. Murphy, P. R. Burd.
1998
. Interferon-γ-dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the CpG-rich promoter active in Epstein-Barr virus-transformed lymphoblastoid cells.
Blood
91
:
4645
56
Kollet, J., C. Witek, J. D. Gentry, X. Liu, S. D. Schwartzbach, T. M. Petro.
2001
. Deletional analysis of the murine IL-12 p35 promoter comparing IFN-gamma and lipopolysaccharide stimulation.
J. Immunol.
167
:
5653
57
Simpson, D. M., A. N. Bender.
1988
. Human immunodeficiency virus-associated myopathy: analysis of 11 patients.
Ann. Neurol.
24
:
79
58
Grunfeld, C., K. R. Feingold.
1992
. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.
N. Engl. J. Med.
327
:
329
59
Macallan, D. C., C. Noble, C. Baldwin, S. A. Jebb, A. M. Prentice, W. A. Coward, M. B. Sawyer, T. J. McManus, G. E. Griffin.
1995
. Energy expenditure and wasting in human immunodeficiency virus infection.
N. Engl. J. Med.
333
:
83
60
Hadigan, C., S. Jeste, E. J. Anderson, R. Tsay, H. Cyr, S. Grinspoon.
2001
. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution.
Clin. Infect. Dis.
33
:
710
61
Dube, M. P..
2000
. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Clin. Infect. Dis.
31
:
1467
62
Kino, T., G. P. Chrousos.
2001
. Acquired immunodeficiency syndrome-related insulin resistance and lipodystrophy: a multifactorial viral and iatrogenic condition.
Endocr. Pract.
7
:
480
63
Yanovski, J. A., K. D. Miller, T. Kino, T. C. Friedman, G. P. Chrousos, C. Tsigos, J. Falloon.
1999
. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
J. Clin. Endocrinol. Metab.
84
:
1925
64
Sarlis, N. J., S. J. Chanock, L. K. Nieman.
2000
. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin.
J. Clin. Endocrinol. Metab.
85
:
42